Toggle Main Menu Toggle Search

Open Access padlockePrints

Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease

Lookup NU author(s): Dr Rachel CrosslandORCiD, Professor Anne Dickinson

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© Copyright © 2020 Crossland, Perutelli, Bogunia-Kubik, Mooney, Milutin Gašperov, Pučić-Baković, Greinix, Weber, Holler, Pulanić, Wolff, Dickinson, Inngjerdingen and Grce.Prognostic, diagnostic or predictive biomarkers are urgently needed for assessment of chronic graft-versus-host disease (cGvHD), a major risk for patients undergoing allogeneic hematopoietic stem cell transplantation. The main goal of this review generated within the COST Action EUROGRAFT “Integrated European Network on Chronic Graft Versus Host Disease” was to identify potential novel biomarkers for cGvHD besides the widely accepted molecular and cellular biomarkers. Thus, the focus was on cellular biomarkers, alloantibodies, glycomics, endothelial derived particles, extracellular vesicles, microbiome, epigenetic and neurologic changes in cGvHD patients. Both host-reactive antibodies in general, and particularly alloantibodies have been associated with cGvHD and require further consideration. Glycans attached to IgG modulate its activity and represent a promising predictive and/or stratification biomarker for cGVHD. Furthermore, epigenetic changes such as microRNAs and DNA methylation represent potential biomarkers for monitoring cGvHD patients and novel targets for developing new treatment approaches. Finally, the microbiome likely affects the pathophysiology of cGvHD; bacterial strains as well as microbial metabolites could display potential biomarkers for dysbiosis and risk for the development of cGvHD. In summary, although there are no validated biomarkers currently available for clinical use to better inform on the diagnosis, prognosis or prediction of outcome for cGvHD, many novel sources of potential markers have shown promise and warrant further investigation using well characterized, multi-center patient cohorts.


Publication metadata

Author(s): Crossland RE, Perutelli F, Bogunia-Kubik K, Mooney N, Milutin Gasperov N, Pucic-Bakovic M, Greinix H, Weber D, Holler E, Pulanic D, Wolff D, Dickinson AM, Inngjerdingen M, Grce M

Publication type: Review

Publication status: Published

Journal: Frontiers in Immunology

Year: 2020

Volume: 11

Print publication date: 01/12/2020

Online publication date: 23/12/2020

Acceptance date: 23/11/2020

ISSN (electronic): 1664-3224

Publisher: Frontiers Media S.A.

URL: https://doi.org/10.3389/fimmu.2020.602547

DOI: 10.3389/fimmu.2020.602547

PubMed id: 33424849


Share